Next Article in Journal
Fast Screening of Protein Tyrosine Phosphatase 1B Inhibitor from Salvia miltiorrhiza Bge by Cell Display-Based Ligand Fishing
Next Article in Special Issue
Drug Repurposing in the Chemotherapy of Infectious Diseases
Previous Article in Journal
Influence of Caffeic and Caftaric Acid, Fructose, and Storage Temperature on Furan Derivatives in Base Wine
Previous Article in Special Issue
Antileishmanial Anthracene Endoperoxides: Efficacy In Vitro, Mechanisms and Structure-Activity Relationships
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 22
10.3390/molecules27227892
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Synthesis and Anti-Leishmanial Properties of Quinolones Derived from Zanthosimuline

by
Gwenaëlle Jézéquel
1,
Laura Nogueira de Faria Cardoso
1,
Florent Olivon
1,
Indira Dennemont
2,
Cécile Apel
1,
Marc Litaudon
1,
Fanny Roussi
1,
Sébastien Pomel
2 and
Sandy Desrat
1,*
1
CNRS, Institut de Chimie des Substances Naturelles, Université Paris-Saclay, UPR 2301, 91198 Gif-sur-Yvette, France
2
CNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France
*
Author to whom correspondence should be addressed.
Molecules 2022, 27(22), 7892; https://doi.org/10.3390/molecules27227892
Submission received: 22 September 2022 / Revised: 27 October 2022 / Accepted: 4 November 2022 / Published: 15 November 2022
(This article belongs to the Special Issue Chemistry of Antiparasitic Drugs)
Browse Figures
Review Reports Versions Notes

Abstract

:
Quinoline derivatives and especially quinolones are considered as privileged structures in medicinal chemistry and are often associated with various biological properties. We recently isolated a series of original monoterpenyl quinolones from the bark of Codiaeum peltatum. As this extract was found to have a significant inhibitory activity against a Leishmania species, we decided to study the anti-leishmanial potential of this type of compound. Leishmaniasis is a serious health problem affecting more than 12 million people in the world. Available drugs cause harmful side effects and resistance for some of them. With the aim of finding anti-leishmanial compounds, we developed a synthetic strategy to access natural quinolones and analogues derived from zanthosimuline. We showed the versatility of this natural compound toward cyclization conditions, leading to various polycyclic quinolone-derived structures. The natural and synthetic compounds were evaluated against amastigote forms of Leishmania infantum. The results obtained confirmed the interest of this family of natural compounds but also revealed promising activities for some intermediates deriving from zanthosimuline. Following the same synthetic strategy, we then prepared 14 new analogues. In this work, we identified two promising molecules with good activities against intramacrophage L. infantum amastigotes without any cytotoxicity. We also showed that slight changes in amide functional groups affect drastically their anti-parasitic activity.

1. Introduction

Leishmaniasis is one of the most extended neglected tropical diseases caused by protozoan parasites from the genus Leishmania, counting more than twenty species and subspecies. This vector-borne disease is transmitted by the bite of an infected female phlebotomine sandfly. In its life cycle, the parasite is present in a mobile flagellated and elongated promastigote form in the sandfly, and in a non-mobile and intracellular form in the mammalian host cells [1]. Depending on the Leishmania species involved, the three main forms of clinical manifestations of leishmaniasis are cutaneous, mucocutaneous, and visceral, which is lethal without treatment [2]. According to the World Health Organization, between 700 000 and 1 000 000 new cases occur each year, causing the death of thousands of people. Great efforts have been made to develop new treatments, but only a few are currently available against leishmaniases. Antimoniates, paromomycin, miltefosine, and liposomal amphotericin B are broadly used, but they present several issues of toxicity, resistance, and cost [3]. To circumvent these limitations, the development of new anti-leishmanial agents is crucial.
We recently selected the bark extract of Codiaeum peltatum using a multi-informative molecular network approach to isolate original natural products and antiviral compounds [4]. The phytochemical investigation of this extract led to the isolation of previously undescribed compounds belonging to three different families (Figure 1): daphnane-type diterpenoid orthoesters (1), 1,4-dioxane-fused phenanthrene dimers (2), and chlorinated monoterpenyl quinolones (3 and 4). Among these, quinolones attracted our attention, because of their low cytotoxicity on Vero cells (CC50 > 200 µM) compared to the other compounds isolated [4] and because of their easy access by synthesis [5,6], facilitating the preparation of various analogs. Furthermore, quinoline derivatives are compounds of choice because they are known to possess a wide range of biological properties including anti-leishmanial activities [7,8,9,10,11,12]. They are considered as privileged structures in drug development [13,14]. In 2005, Billo et al. showed a significant inhibitory activity of the bark extract of Codiaeum peltatum against the promastigote form of Leishmania donovani with an IC50 value of 5 µg/mL [15]. We wondered whether this antiprotozoal activity could be due to quinolone derivatives. To address this question, we have developed the synthesis of natural chloroaustralasine A 3 and a set of analogues of the intermediate zanthosimuline 7, then evaluated their anti-leishmanial potential.

2. Results and Discussion

Chloroaustralasine A 3 was prepared in three steps from commercial sources [5] by hydroxychlorination of the double bond of a tetracyclic intermediate 8 (Scheme 1). This compound was obtained following a biomimetic strategy, i.e., based on an intramolecular hetero Diels–Alder cycloaddition of a geranyl quinolone. First, a Knoevenagel reaction between commercial 4-hydroxy-1-methyl-2(1H)-quinolone 5 and citral 6 allowed the introduction of a geranyl chain and spontaneously led to the oxa 6π electrocyclization product 7 [16,17]. This compound named zanthosimuline was previously isolated from the root bark of Zanthoxylum simulans [18]. Then, a retro oxa 6π electrocyclization/intramolecular hetero-Diels–Alder cascade gave the desired tetracyclic core 8 in a mixture of diastereomers.
To develop an efficient synthetic strategy to access chloroaustralasine A 3, we have investigated various conditions for the retro-electrocyclization/intramolecular Diels–Alder reaction sequence (Table 1). Interestingly, this study revealed the versatility of zanthosimuline 7. Depending on the conditions, this molecule could indeed lead to different racemic heterocycles such as the [4+2] cycloadducts 8 and 9, the polyene cyclization compounds 10 and 11, or the Gassman-like [2+2] cycloadduct 12. A clear identification of all these compounds could be performed by analysis of the NMR and HRMS spectra as shown in supplementary materials. The proton NMR spectrum of zanthosimuline 7 showed a triplet at 5.09 ppm and two doublet signals at 5.48 and 6.79 ppm, characteristic of the olefinic proton of the prenyl chain and the two pyranic protons, respectively. The cyclization led to the disappearance of this triplet from the prenyl chain. The subsequent formation of the double bond in compound 8 resulted in the appearance of a signal at 6.46 ppm, as well as the proton signals from the cycle junction at 3.22 and 3.55 ppm. The NMR spectra of ene cyclization products 10 and 11 were very different. Compound 10 exhibited two proton signals at 3.92 and 4.66 ppm corresponding to the protons of the hydroxypyran cycle whereas these signals disappeared for the dehydrated molecule 11. In addition, a singlet signal corresponding to the pyran proton was observed at 6.70 ppm. Concerning the [2+2] cycloadduct 12, two triplets at 2.46 and 2.66 ppm and a doublet at 3.12 ppm clearly appeared on the proton NMR spectrum in complete accordance with the corresponding cannabicyclol described in the literature [19,20,21].
As described in the literature [6], heating substrate 7 adsorbed on silica at 150 °C gave compound 8, but in only 26% yield in our hands (Table 1, entry 1). Under thermic conditions, the expected Diels–Alder adduct 8 was isolated in moderate yield as a cis/trans mixture 2:1 (entry 2). Brønsted acids such as H2SO4 and PTSA (entries 3,4) mainly led to degradation. Various Lewis acids were then evaluated as promoters in this cascade reaction. Montmorillonite K10, trimethylsilyl chloride, zinc(II) chloride, and iron(III) chloride had almost no effect on zanthosimuline 7 (entries 5, 6, 10, and 11). In the presence of boron trifluoride diethyl etherate, titanium(IV) chloride, or tin(IV) chloride, the expected alkaloid 8 was not formed, but the polyene cyclization products 9 and 10 were obtained (entries 7–9). Compound 10, that resulted from the trapping of the carbocation obtained after the cyclization [18], was obtained as a single diastereoisomer in an excellent 92% yield when using tin(IV) chloride (entry 9), while in some cases it was accompanied by the corresponding hydroxyl elimination product 11. Original intramolecular Gassman-type cationic [2+2] cycloadduct 12 [22] was synthesized by photoredox catalysis in a diastereoselective fashion in the presence of tris(2,2-bipyridine)ruthenium(II) hexafluorophosphate under UV irradiation (entry 15), whereas aluminum(III) chloride led to rapid degradation of the substrate (entry 12). The desired isochromene analog 8 was nonetheless isolated in 55% yield together with compound 9 in 10% yield in the presence of trimethylaluminum (entry 13). This isomer 9 results from the [4+2] cycloaddition on the amide carbonyl instead of the benzophenone one. Both cyclization products 8 and 9 were obtained as a cis/trans mixture (2:1). Finally, the desired tetracyclic compound 8 was obtained quantitatively when using dimethylaluminium chloride (2 eq.) for 18 h at room temperature (entry 14) and these conditions were selected for the synthesis of chloroaustralasine A 3. Compounds 8, 9, and 10 were not stable over time: 8 and 9 led to degradation and must be used directly for further functionalization while 10 dehydrated to give tetracycle 11.
In addition to the natural quinolones 3 and 4, we have evaluated the anti-leishmanial potential of all the stable intermediates (7, 11, and 12) prepared during the optimization of the synthetic route to 3. These compounds were evaluated on L. infantum axenic and intramacrophagic amastigotes and compared to miltefosine as a reference drug (Table 2). Chloroaustralasine A 3 was the most active on axenic amastigotes of L. infantum with an IC50 value of 8 μM and showed almost no cytotoxicity on RAW 264.7 cells (Table 2, entry 1). However, no activity was observed on intramacrophage amastigotes with this compound up to a concentration of 50 µM. Although active against axenic amastigotes, the natural analog 4 was ten times more cytotoxic than 3 (entry 2). These results could partly explain the activity found for the crude ethyl acetate bark extract of Codiaeum peltatum on Leishmania parasites [15]. Zanthosimuline 7 and the pentacyclic derivative 12 revealed a moderate activity on axenic amastigotes and no activity on intramacrophagic amastigotes (entries 3 and 5). In contrast, the tetracyclic quinolone 11 showed a particularly interesting profile (entry 4) without any cytotoxicity and with a promising activity of 14.7 μM on intramacrophage amastigotes, close to the value obtained with miltefosine (entry 6). However, no activity on axenic amastigotes was observed. This compound is effective against the L. infantum parasite but only when the parasite is in the macrophage. This type of host-directed mechanism of action has been previously described in the literature [23,24,25,26,27].
We thus studied pharmacomodulations on the quinolone scaffold by varying the substituents on the amide function of zanthosimuline 7 and on the tetracyclic product 11. Following the same strategy as above, the pyranoquinoline 14 was prepared, and various substituents were then introduced on its amide moiety. The resulting compounds were finally submitted to ene cyclization leading to analogs of alkaloid 11.
The pyranoquinoline 14 [17,27] was obtained in 92% yield after condensation of 1,4-dihydroxyquinoline 13 with citral 6 catalyzed by EDDA (Scheme 2). Then, various bases were evaluated to favor the N-alkylation toward the O-alkylation of the resulting amide 14. Sodium hydride gave the lowest proportion of O-alkylated products (< 10%) and was chosen to introduce various alkyl (15a–g, 15k–l), sulfonyl (15h), and acyloxy (15i and 15j) substituents. All the products were obtained in good yields except the benzyl carbamate analog 15h, which was isolated with a yield of 18% because of degradation of the substrate 14. Whatever the base used, no acyl group could be added to the nitrogen atom. The methyl pentanoate chain of compound 15k was hydrolyzed in basic conditions to obtain the corresponding carboxylic acid derivative 15l. Twelve analogs 15a–l of zanthosimuline 7 were prepared using this strategy.
To obtain the corresponding tetracyclic derivatives 16a–l, the functionalized alkaloids 15a–l were finally submitted to ene cyclization in the presence of tin(IV) chloride, as previously described. However, most of the compounds 15a–l led to degradation in these conditions, and no trace of desired cyclized 16a-l were detected, except for the benzylated derivative 16a, which was isolated in 57% yield (Scheme 3). We then tried other Lewis acids, such as boron trifluoride diethyl etherate and titanium(IV) chloride, that also enabled this type of cyclization (Table 1), but degradation was observed. It seems that this type of cyclization is substrate dependent. It gave the expected compound only with the N-methyl and N-benzyl derivatives (7 and 15a).
All the compounds prepared (14, 15a–l, and 16a) were evaluated on L. infantum axenic and intramacrophage amastigotes and compared to miltefosine as a reference drug (Table 3).
All compounds but 15g and 15h (entries 8 and 9) displayed better activities than compound 7 against axenic amastigotes with IC50 between 7 and 22 µM. However, most of them do not act on the intramacrophage parasites and have a low selectivity index. In this series, only zanthosimuline analogs 15a and 15k show a different profile and inhibit the intramacrophage parasite at 23.7 µM and 19.0 µM, respectively (entries 2 and 12). The benzylated derivative 15a is the most promising compound with a good selectivity index, above 4.2 (entry 2). In comparison with zanthosimuline 7, the addition of a benzyl group is beneficial for the anti-leishmanial activity. However, contrary to compound 11, the cyclization of the alkenyl chain of the benzylated derivative 15a giving compound 16a led to the loss of activity on the intramacrophage form of the parasite and therefore to a low selectivity index (entry 14).
This study reveals the potential of zanthosimuline-derived quinolones against Leishmania parasites. On one hand, the natural chloroaustralasine compounds (3 and 4) could, at least partly, be responsible for the activity previously observed with the crude ethyl acetate bark extract of Codiaeum peltatum. On the other hand, some by-products obtained in developing a synthetic route toward the natural quinolones showed interesting therapeutic profiles. For example, alkaloid 11 showed an interesting inhibitory activity of 14.7 μM on intramacrophage L. infantum amastigotes without any cytotoxicity. With a selectivity index over 6.8, this compound (11) displayed anti-leishmanial properties on intramacrophage amastigotes close to miltefosine, the reference compound. We have also shown that small modifications of the amide function can have an impact on their anti-parasitic activity. Whereas the addition of a benzyl group on the zanthosimuline core improved the growth inhibition of L. infantum, other functionalization led to the loss of any activity.

3. Materials and Methods

3.1. General Experimental Details

All reagents and solvents were used as purchased from commercial suppliers or were purified/dried according to Armarego and Chai [28]. Purifications by column chromatography on silica gel were performed using Merck Silica Gel 60 (70–230 mesh). 1H and 13C NMR spectra were recorded on Bruker ARX500 instruments using CDCl3 as an internal reference. Chemical shifts (δ values) are given in parts per million (ppm), and the multiplicity of signals is reported as follows: s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet. HRMS analyses were performed using a Waters LCT Premier instrument by positive ion mode ElectroSpray Ionization (ESI+). A Monowave 50 appartus from Anton-Paar was used with a thermic control (Pmax: 315 W).

3.2. Procedures and Analytical Description of Compounds

Zanthosimuline 7. A suspension of 4-hydroxy-1-methyl-2-(1H)-quinolone 5 (1.50 g, 8.56 mmol, 1 eq.), citral 6 (1.47 mL, 8.56 mmol, 1 eq.), and EDDA (0.30 g, 1.71 mmol, 0.2 eq.) in anhydrous EtOH (15 mL) was heated under MW irradiation at 150 °C for 20 min. The mixture was concentrated under reduced pressure and the desired compound purified by flash chromatography on silica gel (80 g) using heptane/EtOAc from 10:0 to 5:5 to give zanthosimuline 7 as a light-yellow oil (2.45 g, 7.91 mmol, 92%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.93 (d, J = 7.9 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 6.77 (d, J = 10.0 Hz, 1H), 5.46 (d, J = 10.0 Hz, 1H), 5.07 (t, J = 7.0 Hz, 1H), 3.67 (s, 3H), 2.12 (q, J = 7.0 Hz, 2H), 1.82–1.62 (m, 2H), 1.60 (s, 3H), 1.52 (s, 3H), 1.45 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 161.2, 155.6, 139.5, 132.2, 131.0, 125.4, 123.9, 123.3, 121.9, 118,6, 116.2, 114.2, 105.7, 81.5, 41.7, 29.5, 27.2, 25.8, 22.8, 17.8 ppm. HRMS (ESI+): calcd. for C20H24NO2+ [M+H]+ 310.1802, found 310.1804. Analytical data were consistent with those described by Wu and Chen [18].
6,6,9,12-Tetramethyl-6,6a,7,8,10a,12-hexahydro-11H-isochromeno [4,3-c]quinolin-11-one (8). To a solution of zanthosimuline 7 (198 mg, 0.64 mmol, 1 eq.) in anhydrous dichloromethane (6 mL) under Ar atm. was added a 1 M solution of Me2AlCl in hexanes (1.28 mL, 1.28 mmol, 2 eq.). The reaction mixture was stirred at RT for 18 h before adding 0.5 mL of water. The mixture was dried over MgSO4, filtrated over a Celite® pad, and concentrated under reduced pressure to give compound 8 in a cis/trans mixture (2:1) as a pale-yellow oil (196 mg, 0.64 mmol, 95%). 1H NMR of cis-8 (500 MHz, CDCl3, 25 °C): δ 7.93 (dd, J = 8.0, 1.3 Hz, 1H), 7.48 (bt, J = 8.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.17 (bt, J = 7.7 Hz, 1H), 6.47−6.41 (m, 1H), 3.66 (s, 3H), 3.55 (bs, 1H), 2.03−1.87 (m, 3H), 1.87−1.75 (m, 1H), 1.69 (bs, 3H), 1.51 (s, 3H), 1.44−1.32 (m, 1H), 1.31 (s, 3H) ppm. 1H NMR of trans-8 (500 MHz, CDCl3, 25 °C): δ 7.93 (dd, J = 8.0, 1.3 Hz, 1H), 7.48 (bt, J = 8.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H), 7.17 (bt, J = 7.7 Hz, 1H), 6.47−6.41 (m, 1H), 3.67 (s, 3H), 3.24–3.19 (m, 1H), 2.23−2.12 (m, 2H), 2.03−1.87 (m, 1H), 1.75−1.62 (m, 1H), 1.69 (bs, 3H), 1.53 (s, 3H), 1.54−1.43 (m, 1H), 1.14 (s, 3H) ppm. HRMS (ESI+): calcd. for C20H24NO2+ [M+H]+ 310.1802, found 310.1812. Analytical data were consistent with those described by Riveira et al. [6].
Chloroaustralasine A 3. To a solution of cis/trans-8 (44 mg, 0.14 mmol, 1 eq.) in a 1:3 mixture of tert-butanol/citric acid buffer (0.1 M, pH 3.5, 14 mL) were added an aqueous suspension of chloroperoxidase (3000 U/mL) from Caldariomyces fumago (40 µL, 120 U) and NaCl (8 mg, 0.14 mmol, 1 eq.). Then, a 30% H2O2 aqueous solution (20 µL, 0.16 mmol, 1 eq.) was added portion wise every 10 min for 1 h. The products were then extracted twice with MTBE (14 mL). The combined organic phases were dried over MgSO4 and concentrated in vacuo. The residue was purified by semi-preparative HPLC (Kinetex C18, H2O-MeCN 45:55 at 4.7 mL·min−1) to afford chloroaustralasine A 3 as a white powder (12 mg, 0.033 mmol, 24%, tR: 13.3 min). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.98 (dd, J = 8.0, 1.4 Hz, 1H), 7.55 (ddd, J = 8.5, 7.1, 1.4 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.23 (dd, J = 8.0, 7.1 Hz, 1H), 5.81 (s, 1H), 3.70 (s, 3H), 3.60 (dd, J = 11.4, 2.6 Hz, 1H), 2.17 (ddd, J = 12.0, 11.4, 3.6 Hz 1H), 1.93 (ddd, J = 13.7, 12.9, 5.1 Hz, 1H), 1.72–1.46 (m, 3H), 1.53 (s, 3H), 1.43 (s, 3H), 1.18 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 162.9, 157.5, 139.0, 130.6, 123.4, 121.8, 116.9, 114.1, 106.3, 79.8, 72.4, 65.5, 40.1, 36.0, 32.9, 29.6, 29.4, 27.6, 22.9, 19.8 ppm. HRMS (ESI+): calcd. for C20H25ClNO3+ [M+H]+ 362.1515, found 362.1515. [5]
7-Hydroxy-5,8,8,11a-tetramethyl-5,7,7a,8,9,10,11,11a-octahydro-6H-chromeno [3,2-c]quinolin-6-one (10). To a solution of zanthosimuline 7 (350 mg, 1.13 mmol, 1 eq.) in anhydrous dichloromethane (10 mL) under Ar atm. was added dropwise BF3.OEt2 (280 µL, 2.26 mmol, 2 eq.). After 18 h at RT, the mixture was quenched with water (0.3 mL). MgSO4 was added to the solution and the solids were eliminated by filtration over a Celite® pad. The filtrate was concentrated under reduced pressure and purified by flash chromatography on silica gel (24 g) with heptane/EtOAc from 10:0 to 0:10 to give compound 11 as a white solid (98 mg, 0.32 mmol, 28%) and compound 10 as a yellow gum (112 mg, 0.334 mmol, 30%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 8.02 (d, J = 8.0 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 4.78 (s, 1H), 3.73 (s, 3H), 2.24 (d, J = 14.5 Hz, 1H), 1.83 (qt, J = 13.8, 3.0 Hz, 1H), 1.74 (s, 1H), 1.62 (td, J = 13.8, 4.0 Hz, 1H), 1.55–1.42 (m, 2H), 1.42 (s, 3H), 1.33 (td, J = 13.8, 3.0 Hz, 1H), 1.29–1.23 (m, 1H), 1.11 (s, 3H), 0.60 (s, 3H) ppm. 13C NMR (125 MHz, CD3CN, 25 °C): δ 164.3, 156.4, 140.1, 132.0, 124.0, 122.7, 117.0, 115.5, 110.0, 79.1, 62.9, 52.6, 41.7, 39.6, 33.5, 32.0, 29.3, 26.9, 21.3, 18.6 ppm. HRMS (ESI+): calcd. for C20H25NO3+ [M+H]+ 328.1907, found 328.1897. Compound 10 was found to be unstable over a period of one week, giving compound 11.
5,8,8,11a-Tetramethyl-5,8,9,10,11,11a-hexahydro-6H-chromeno [3,2-c]quinolin-6-one (11). To a solution of zanthosimuline 7 (50 mg, 0.16 mmol, 1 eq.) in anhydrous dichloromethane (5 mL) under Ar atm. was added SnCl4 (84 mg, 0.32 mmol, 2 eq.). After 1 h at RT, the mixture was quenched with water (0.2 mL). MgSO4 was added to the solution and the solids were eliminated by filtration over a Celite® pad. The filtrate was concentrated under reduced pressure and purified by flash chromatography on silica gel (24 g) with heptane/EtOAc from 10:0 to 5:5 to give compound 11 as a white solid (46 mg, 0.15 mmol, 95%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.91 (d, J = 7.9 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 6.68 (d, J = 10.0 Hz, 1H), 3.69 (s, 3H), 2.19 (m, 1H), 1.97 (dt, J = 12.9, 5.0 Hz, 1H), 1.72–1.69 (m, 2H), 1.50−1.43 (m, 1H), 1.44 (s, 3H), 1.28 (s, 3H), 1.17 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 161.4, 153.9, 144.4, 139.2, 130.6, 123.1, 121.9, 116.4, 114.2, 112.4, 108.1, 80.8, 40.1, 39.6, 36.1, 31.0, 30.8, 29.5, 25.8, 19.2 ppm. HRMS (ESI+): calcd. for C20H24NO2+ [M+H]+ 310.1802, found 310.1799.
1,1,3a,9-Tetramethyl-1,1a,1a1,2,3,3a,9,10b-octahydro-10H-4-oxa-9-azacyclobuta [7,1]indeno [5,6-a]naphthalen-10-one (12). To a solution of zanthosimuline 7 (50 mg, 0.16 mmol, 1 eq.) in anhydrous nitromethane (1 mL) under Ar atm. were added Ru(bpy)3(PF6)2 (7 mg, 0.01 mmol, 5 mol%) and methyl viologen (6 mg, 0.02 mmol, 10 mol%). After 1 h under blue light irradiation at RT, the mixture was concentrated under reduced pressure and the product was purified by flash chromatography on silica gel (24 g) with heptane/EtOAc from 10:0 to 5:5 to give compound 12 as a yellow gum (43 mg, 0.14 mmol, 86%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 8.00 (dd, J = 8.0, 1.4 Hz, 1H), 7.53 (td, J = 8.0, 1.4 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 3.68 (s, 3H), 3.13 (d, J = 9.2 Hz, 1H), 2.66 (dd, J = 9.8, 7.6 Hz, 1H), 2.46 (t, J = 7.6 Hz, 1H), 2.04–1.95 (m 1H), 1.79–1.69 (m, 2H), 1.67–1.58 (m, 1H), 1.51 (s, 3H), 1.46 (s, 3H), 0.84 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 163.5, 155.1, 138.8, 130.0, 122.9, 121.3, 117.0, 113.7, 109.1, 85.2, 46.8, 39.5, 39.1, 38.0, 36.9, 33.8, 29.2, 27.5, 26.0, 17.6 ppm. HRMS (ESI+): calcd. for C20H24NO2+ [M+H]+ 310.1802, found 310.1807 [21].
2-Methyl-2-(4-methylpent-3-en-1-yl)-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (14). A suspension of 1,4-dihydroxyquinoline 13 (3.00 g, 18.6 mmol, 1 eq.), citral 6 (3.19 mL, 18.6 mmol, 1 eq.), and EDDA (0.66 g, 3.72 mmol, 0.2 eq.) in anhydrous EtOH (40 mL) was heated under MW irradiation at 150 °C for 30 min. After decanting for 10 min, the supernatant containing the expected compound was removed. The solids were rinsed twice with EtOH. The combined supernatants were then concentrated under reduced pressure to obtain a light-orange solid (4.78 g, 16.2 mmol, 87%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 11.57 (bs, 1H), 7.87 (dd, J = 8.1, 1.4 Hz, 1H), 7.47 (td, J = 7.2, 1.2 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.19 (t, J = 7.9, 1H), 6.81 (d, J = 10.1 Hz, 1H), 5.50 (d, J = 10.1 Hz, 1H), 5.10 (tt, J = 7.1, 1.3 Hz, 1H), 2.16 (q, J = 7.9 Hz, 2H), 1.89–1.73 (m, 2H), 1.63 (s, 3H), 1.55 (s, 3H), 1.51 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 163.1, 157.6, 138.3, 132.0, 130.8, 125.1, 123.9, 122.5, 122.1, 117.8, 116.3, 115.2, 105.4, 81.7, 41.7, 27.2, 25.7, 22.7, 17.7 ppm. HRMS (ESI+): calcd. for C19H21NO2+ [M+H]+ 296.1645, found 296.1646. Analytical data were consistent with those described in the literature [17,27].
General procedure for functionalization of compound 14. To a solution of compound 14 (50 mg, 0.17 mmol, 1 eq.) in anhydrous DMF (2.5 mL), at 0 °C and under Ar atm., was added NaH (60% in mineral oil, 8 mg, 0.20 mmol, 1.2 eq.). The suspension was stirred for 30 min at 0 °C and the electrophile was added (1–2 eq.). The reaction mixture was allowed to warm to RT and stirred for 6 to 18 h. A saturated solution of NH4Cl was then added and the product was extracted with EtOAc (3 times). The combined organic phases were dried over MgSO4, filtered, and concentrated under reduced pressure. A purification by flash column chromatography on silica gel with heptane/EtOAc as eluent gave the desired pure compound.
6-Benzyl-2-methyl-2-(4-methylpent-3-en-1-yl)-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15a). Following the general procedure described with benzyl bromide as the electrophile, compound 15a was isolated as a light-yellow oil (43 mg, 0.11 mmol, 66%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.96 (dd, J = 8.0, 1.3 Hz, 1H), 7.37 (dt, J = 8.0, 1.3 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H), 7.23–7.18 (m, 4H), 7.15 (t, J = 7.3 Hz, 1H), 6.84 (d, J = 10.0 Hz, 1H), 5.50 (d, J = 10.0 Hz, 1H), 5.11 (t, J = 7.0 Hz, 1H), 2.16 (q, J = 7.0 Hz, 2H), 1.91–1.84 (m, 1H), 1.80–1.73 (m, 1 H), 1.62 (s, 3H), 1.56 (s, 3H), 1.50 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 161.1, 155.7, 138.8, 136.8, 131.9, 130.8, 128.7 (2C), 127.1, 126.5 (2C), 125.2, 123.7, 123.1, 121.7, 118.4, 116.2, 114.8, 105.2, 81.5, 45.7, 41.6, 27.1, 25.6, 22.6, 17.6 ppm. HRMS (ESI+): calcd. for C26H27NO2+ [M+H]+ 386.2115, found 386.2130.
6-(3-Methoxybenzyl)-2-methyl-2-(4-methylpent-3-en-1-yl)-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15b). Following the general procedure described with 3-methoxybenzyl bromide as the electrophile, compound 15b was isolated as a light-yellow oil (45 mg, 0.11 mmol, 67%). 1H NMR (500 MHz, CDCl3, 25 °C): 7.96 (dd, J = 8.0, 1.3 Hz, 1H), 7.37 (dt, J = 8.0, 1.3 Hz, 1H), 7.23–7.15 (m, 3H), 6.84 (d, J = 10.0 Hz, 1H), 6.80 (d, J = 7.8 Hz, 1H), 6.78–6.74 (m, 2H), 5.51 (d, J = 10.0 Hz, 1H), 5.12 (t, J = 7.0 Hz, 1H), 3.75 (s, 3H), 2.17 (q, J = 7.0 Hz, 2H), 1.92–1.85 (m, 1H), 1.81–1.74 (m, 1 H), 1.64 (s, 3H), 1.57 (s, 3H), 1.51 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 161.1, 160.0, 155.7, 138.9, 138.5, 132.0, 130.8, 129.8, 125.2, 123.7, 123.1, 121.8, 118.8, 118.4, 116.2, 114.9, 112.6, 112.2, 105.2, 81.5, 55.2, 45.7, 41.6, 27.1, 25.6, 22.6, 17.6 ppm. HRMS (ESI+): calcd. for C27H30NO3+ [M+H]+ 416.2220, found 416.2229.
2-Methyl-2-(4-methylpent-3-en-1-yl)-6-(pyridin-2-ylmethyl)-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15c). Following the general procedure described with 2-(bromomethyl)pyridine as the electrophile, compound 15c was isolated as a yellow oil (53 mg, 0.14 mmol, 80%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 8.57 (d, J = 4.8 Hz, 1H), 7.95 (dd, J = 8.0, 1.3 Hz, 1H), 7.55 (dt, J = 8.0, 1.3 Hz, 1H), 7.43–7.35 (m, 2H), 7.20–7.12 (m, 3H), 6.84 (d, J = 10.0 Hz, 1H), 5.65 (bs, 2H), 5.52 (d, J = 10.0 Hz, 1H), 5.11 (t, J = 7.0 Hz, 1H), 2.16 (q, J = 7.0 Hz, 2H), 1.91–1.84 (m, 1H), 1.80–1.73 (m, 1 H), 1.63 (s, 3H), 1.56 (s, 3H), 1.50 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 161.1, 157.1, 155.9, 149.2, 138.9, 136.9, 132.0, 130.9, 125.2, 123.7, 123.1, 122.3, 121.9, 121.5, 118.3, 116.2, 115.1, 105.2, 81.6, 48.0, 41.6, 27.1, 25.6, 22.6, 17.6 ppm. HRMS (ESI+): calcd. for C25H27N2O2+ [M+H]+ 387.2067, found 387.2064.
6-(2-Methoxyethyl)-2-methyl-2-(4-methylpent-3-en-1-yl)-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15d). Following the general procedure described with 2-bromomethyl methyl ether as the electrophile, compound 15d was isolated as a yellow oil (37 mg, 0.11 mmol, 64%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.95 (dd, J = 8.0, 1.2 Hz, 1H), 7.54–7.50 (m, 1H), 7.49 (t, J = 8.0 Hz, 1H), 7.23 (td, J = 8.0, 1.0 Hz, 1H), 6.80 (d, J = 10.0 Hz, 1H), 5.48 (d, J = 10.0 Hz, 1H), 5.09 (t, J = 6.9 Hz, 1H), 4.47 (t, J = 6.1 Hz, 2H), 3.71 (t, J = 6.1 Hz, 2H), 3.36 (s, 3H), 2.14 (q, J = 7.8 Hz, 2H), 1.89–1.81 (m, 1H), 1.78–1.68 (m, 1H), 1.62 (s, 3H), 1.55 (s, 3H), 1.48 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 160.9, 155.6, 139.2, 132.0, 130.7, 125.2, 123.8, 123.1, 121.7, 118.2, 116.1, 114.6, 105.2, 81.4, 70.1, 59.1, 42.1, 41.6, 27.1, 25.6, 22.6, 17.6 ppm. HRMS (ESI+): calcd. for C22H28NO3+ [M+H]+ 354.2064, found 354.2060.
2-Methyl-6-(3-methylbut-2-en-1-yl)-2-(4-methylpent-3-en-1-yl)-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15e). Following the general procedure described with prenyl bromide as the electrophile, compound 15e was isolated as a yellow oil (45 mg, 0.13 mmol, 75%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.95 (dd, J = 8.0, 1.2 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.49 (t, J = 8.0 Hz, 1H), 7.26 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.80 (d, J = 10.0 Hz, 1H), 5.45 (d, J = 10.0 Hz, 1H), 5.14 (t, J = 6.0 Hz, 1H), 5.09 (t, J = 6.9 Hz, 1H), 4.91 (d, J = 6.0 Hz, 2H), 2.14 (q, J = 7.7 Hz, 2H), 1.89 (s, 3H), 1.89–1.81 (m, 1H), 1.78–1.68 (m, 1H), 1.71 (s, 3H), 1.62 (s, 3H), 1.55 (s, 3H), 1.47 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 160.7, 155.4, 138.8, 135.6, 131.9, 130.6, 125.2, 123.8, 123.1, 121.5, 119.8, 118.4, 116.2, 114.5, 104.4, 81.2, 41.6, 40.6, 27.0, 25.6 (2C), 22.7, 18.3, 17.6 ppm. HRMS (ESI+): calcd. for C24H30NO2+ [M+H]+ 364.2271, found 364.2276.
2-Methyl-2-(4-methylpent-3-en-1-yl)-6-phenethyl-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15f). Following the general procedure described with 4-phenethyl bromide as the electrophile, compound 15f was isolated as a yellow oil (42 mg, 0.11 mmol, 62%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.99 (dd, J = 7.5, 1.3 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 7.39–7.31 (m, 6H), 7.22 (t, J = 8.0 Hz, 1H), 6.81 (d, J = 10.0 Hz, 1H), 5.50 (d, J = 10.0 Hz, 1H), 5.11 (t, J = 6.0 Hz, 1H), 4.49–4.44 (m, 2H), 3.04–2.99 (m, 2H), 2.16 (q, J = 7.7 Hz, 2H), 1.90–1.82 (m, 1H), 1.80–1.72 (m, 1H), 1.63 (s, 3H), 1.56 (s, 3H), 1.50 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 160.6, 155.4, 138.6, 138.5, 132.0, 130.8, 128.8 (2C), 128.7 (2C), 126.6, 125.4, 123.8, 123.4, 121.6, 118.2, 116.2, 113.8, 105.4, 81.4, 43.8, 41.6, 34.0, 27.1, 25.6, 22.6, 17.6 ppm. HRMS (ESI+): calcd. for C27H30NO2+ [M+H]+ 400.2271, found 400.2266.
2-Methyl-2-(4-methylpent-3-en-1-yl)-6-pentyl-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15g). Following the general procedure described with 1-bromopentane as the electrophile, compound 15g was isolated as a yellow oil (51 mg, 0.14 mmol, 82%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.96 (dd, J = 8.0, 1.2 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 6.80 (d, J = 10.0 Hz, 1H), 5.47 (d, J = 10.0 Hz, 1H), 5.10 (t, J = 6.0 Hz, 1H), 4.25 (dd, J = 10.5, 7.6 Hz, 2H), 2.14 (q, J = 7.7 Hz, 2H), 1.89–1.81 (m, 1H), 1.78–1.68 (m, 3H), 1.62 (s, 3H), 1.55 (s, 3H), 1.47 (s, 3H), 1.46–1.36 (m, 4H), 0.93 (t, J = 7.6 Hz, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 160.7, 155.2, 138.4, 131.9, 130.7, 125.2, 123.8, 123.2, 121.4, 118.4, 116.2, 114.0, 105.4, 81.2, 42.2, 41.6, 29.2, 27.4, 27.0, 25.6, 22.6, 22.5, 17.6, 14.0 ppm. HRMS (ESI+): calcd. for C24H32NO2+ [M+H]+ 366.2428, found 366.2428.
2-Methyl-2-(4-methylpent-3-en-1-yl)-6-(phenylsulfonyl)-2,6-dihydro-5H-pyrano [3,2-c]quinolin-5-one (15h). Following the general procedure described with 1-bromopentane as the electrophile, compound 15h was isolated as a yellow oil (34 mg, 0.08 mmol, 47%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 8.18 (d, J = 7.5Hz, 2H), 8.0 (dd, J = 7.5, 1.3 Hz, 1H), 7.69–7.63 (m, 2H), 7.60–7.55 (m, 3H), 7.41 (t, J = 8.0 Hz, 1H), 6.67 (d, J = 10.0 Hz, 1H), 5.51 (d, J = 10.0 Hz, 1H), 5.07 (t, J = 6.0 Hz, 1H), 2.14 (q, J = 7.7 Hz, 2H), 1.91–1.83 (m, 1H), 1.81–1.72 (m, 1H), 1.60 (s, 3H), 1.51 (s, 3H), 1.25 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 158.7, 152.2, 145.7, 137.6, 132.2, 130.3, 129.1 (2C), 128.8 (2C), 128.2, 128.1, 125.6, 123.5, 121.8, 118.8, 116.5, 103.7, 82.0, 41.7, 29.7, 27.3, 25.6, 22.5, 17.6 ppm. HRMS (ESI): calcd. for C25H26NO4S+ [M+H]+ 436.1577, found 436.1570.
Phenyl 2-methyl-2-(4-methylpent-3-en-1-yl)-5-oxo-2H-pyrano [3,2-c]quinoline-6(5H)-carboxylate (15i). Following the general procedure described with phenyl chloroformate as the electrophile, compound 15i was isolated as a yellow oil (13 mg, 0.03 mmol, 18%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.97 (dd, J = 8.0, 1.3 Hz, 1H), 7.55 (dt, J = 8.0, 1.3 Hz, 1H), 7.50–7.45 (m, 2H), 7.44–7.40 (m, 2H), 7.36–7.25 (m, 3H), 6.74 (d, J = 10.0 Hz, 1H), 5.52 (d, J = 10.0 Hz, 1H), 5.10 (t, J = 7.0 Hz, 1H), 2.16 (q, J = 7.0 Hz, 2H), 1.93–1.86 (m, 1H), 1.81–1.74 (m, 1 H), 1.63 (s, 3H), 1.57 (s, 3H), 1.52 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 159.5, 157.2, 152.1, 151.0, 135.8, 132.2, 131.3, 129.8 (2C), 126.9, 125.5, 123.5, 123.4, 123.3, 120.9 (2C), 117.1, 115.5, 113.9, 104.9, 82.4, 41.7, 27.3, 25.6, 22.6, 17.6 ppm. HRMS (ESI+): calcd. for C26H26NO4+ [M+H]+ 416.1856, found 416.1854.
tert-Butyl 2-methyl-2-(4-methylpent-3-en-1-yl)-5-oxo-2H-pyrano [3,2-c]quinoline-6(5H)-carboxylate (15j). Following the general procedure described with phenyl chloroformate as the electrophile, compound 15j was isolated as a yellow oil (49 mg, 0.13 mmol, 74%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 8.07 (d, J = 8.2 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.62 (dt, J = 7.4, 1.3 Hz, 1H), 7.43 (t, J = 7.4 Hz, 1H), 6.49 (d, J = 10.0 Hz, 1H), 5.61 (d, J = 10.0 Hz, 1H), 5.09 (t, J = 7.0 Hz, 1H), 2.16 (q, J = 7.2 Hz, 2H), 1.92–1.85 (m, 1H), 1.82–1.75 (m, 1 H), 1.61 (s, 3H), 1.57 (s, 9H), 1.53 (s, 3H), 1.52 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 158.5, 153.0, 150.6, 146.3, 132.1, 130.2, 128.4, 128.1, 125.4, 123.5, 121.7, 119.9, 116.5, 104.3, 84.0, 81.6, 41.7, 27.7 (3C), 27.2, 25.5, 22.5, 17.5 ppm. HRMS (ESI+): calcd. for C24H30NO4+ [M+H]+ 396.2169, found 396.2177.
Methyl 5-(2-methyl-2-(4-methylpent-3-en-1-yl)-5-oxo-2H-pyrano [3,2-c]quinolin-6(5H)-yl)pentanoate (15k). Following the general procedure described with methyl 5-bromovalerate as the electrophile, compound 15k was isolated as a yellow oil (41 mg, 0.10 mmol, 59%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.96 (dd, J = 8.0, 1.2 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 6.77 (d, J = 10.0 Hz, 1H), 5.48 (d, J = 10.0 Hz, 1H), 5.10 (t, J = 6.0 Hz, 1H), 4.28 (t, J = 6.6 Hz, 2H), 3.66 (s, 3H), 2.40 (t, J = 6.6 Hz, 2H), 2.14 (q, J = 7.7 Hz, 2H), 1.88–1.70 (m, 6H), 1.62 (s, 3H), 1.55 (s, 3H), 1.47 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 173.8, 160.7, 155.3, 138.5, 131.9, 130.8, 125.3, 123.8, 123.3, 121.6, 118.3, 116.2, 113.9, 105.3, 81.3, 51.3, 41.7, 41.6, 33.7, 27.2, 27.1, 25.6, 22.6, 22.4, 17.6 ppm. HRMS (ESI+): calcd. for C25H32NO4+ [M+H]+ 410.2326, found 410.2322.
5-(2-Methyl-2-(4-methylpent-3-en-1-yl)-5-oxo-2H-pyrano [3,2-c]quinolin-6(5H)-yl)pentanoic acid (15l). To a solution of ester derivative 15k (25 mg, 0.06 mmol, 1 eq.) in a 1:1 mixture of MeOH/H2O was added LiOH.H2O (7 mg, 0.18 mmol, 3 eq.). The mixture was stirred at RT for 18 h and quenched with a 1 M aqueous solution of HCl. The product was extracted 3 times with MTBE. The combined organic phases were dried over MgSO4, filtered, and concentrated under reduced pressure. A purification by flash chromatography on silica gel (12 g) with heptane/EtOAc from 8:2 to 0:10 gave compound 15k as a yellow oil (19 mg, 0.05 mmol, 80%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.97 (dd, J = 8.0, 1.2 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 6.77 (d, J = 10.0 Hz, 1H), 5.48 (d, J = 10.0 Hz, 1H), 5.09 (t, J = 7.0 Hz, 1H), 4.30 (t, J = 6.0 Hz, 2H), 2.46 (t, J = 6.0 Hz, 2H), 2.14 (q, J = 7.7 Hz, 2H), 1.89–1.70 (m, 6H), 1.62 (s, 3H), 1.55 (s, 3H), 1.47 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 178.0, 160.9, 155.6, 138.4, 132.0, 130.9, 125.4, 123.7, 123.3, 121.8, 118.2, 116.2, 114.1, 105.2, 81.5, 41.8, 41.6, 33.7, 27.1, 27.0, 25.6, 22.6, 22.1, 17.6 ppm. HRMS (ESI+): calcd. for C24H30NO4+ [M+H]+ 396.2169, found 396.2178.
5-Benzyl-8,8,11a-trimethyl-5,8,9,10,11,11a-hexahydro-6H-chromeno [3,2-c]quinolin-6-one (16a). To a solution of N-benzyl quinolone 15a (50 mg, 0.16 mmol, 1 eq.) in anhydrous dichloromethane (5 mL) under Ar atm. was slowly added SnCl4 (84 mg, 0.32 mmol, 2 eq.). After 1 h at RT, the mixture was quenched with water (0.2 mL). MgSO4 was added to the solution and the solids were eliminated by filtration over a Celite® pad. The filtrate was concentrated under reduced pressure and purified by flash chromatography on silica gel (24 g) with heptane/EtOAc from 10:0 to 5:5 to give compound 16a as a white solid (29 mg, 0.09 mmol, 57%). 1H NMR (500 MHz, CDCl3, 25 °C): δ 7.96 (dd, J = 7.9, 1.0 Hz, 1H), 7.36 (td, J = 8.0, 1.0 Hz, 1H), 7.23 (t, J = 8.0 Hz, 1H), 7.18 (t, J = 8.0 Hz, 2H), 7.13 (t, J = 8.0 Hz, 3H), 5.49 (bs, 2H), 4.78 (s, 1H), 2.19 (d, J = 13.6 Hz, 1H), 1.78 (dt, J = 13.6, 7.4 Hz, 1H), 1.71 (s, 1H), 1.56 (td, J = 13.9, 9.6 Hz, 1H), 1.48–1.45 (m, 1H), 1.40 (s, 3H), 1.29 (td, J = 13.9, 9.6 Hz, 1H), 1.07 (s, 3H), 0.57 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3, 25 °C): δ 164.1, 156.4, 138.5, 136.6, 130.9, 128.8 (2C), 127.3, 126.5 (2C), 123.7, 122.0, 116.8, 114.9, 109.0, 78.6, 62.4, 52.0, 45.6, 41.3, 39.2, 33.0, 31.7, 26.7, 21.2, 17.9 ppm. HRMS (ESI+): calcd. for C26H28NO2+ [M+H]+ 386.2115, found 386.2125.

3.3. Cell Cultures

Promastigotes of Leishmania infantum (MHOM/FR/2008/LEM5700) were cultured in the dark at 26 °C with 5% CO2 in M199 complete medium containing M199 medium supplemented with adenosine (100 µM), hemin (0.5 mg/L), Hepes (40 mM) pH 7.4, and heat-inactivated fetal bovine serum (10%; HIFBS). Cultures of axenic amastigotes of L. infantum were adapted from [29]. Briefly, axenic amastigotes of L. infantum were obtained from late log promastigotes diluted at 1 × 106/mL in M199 complete medium acidified at pH 5.5 and cultured at 37 °C with 5% CO2.
The RAW 264.7 macrophages (ATCC) were cultured at 37 °C with 5% CO2 in DMEM complete medium containing Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen, Thermo-Fisher, Villebon-sur-Yvette, France) supplemented with penicillin-streptomycin (100 U/mL; Invitrogen) and heat-inactivated fetal bovine serum (10%; HIFBS).

3.4. In Vitro Cytotoxicity Evaluation of Compounds

Cytotoxicity was evaluated on RAW 264.7 macrophages [26]. Cells were plated in 96-well microplates at a density of 2 × 104 cells per well. After an incubation of 24 h at 37 °C with 5% CO2, the medium was removed from each well, and 100 µL of DMEM complete medium containing two-fold serial dilutions of the compounds, from 100 µM to 0.049 µM, was added to each well. After 48 h of incubation at 37 °C with 5% CO2, 10 µL of resazurin (450 µM) was added to each well and further incubated in the dark for 4 h at 37 °C with 5% CO2. In living cells, resazurin is reduced in resorufin, and this conversion is monitored by measuring OD570nm (resorufin) and OD600nm (resazurin; multimode microplate reader Spark®, Tecan, Lyon, France). The cytotoxicity of the compounds was expressed as CC50 (Cytotoxic Concentration 50%: concentration inhibiting macrophage metabolic activity by 50%) and was determined by nonlinear regression in GraphPad Prism 7.0. In vitro cytotoxicity assays were performed in triplicate in three independent experiments.

3.5. In Vitro Antileishmanial Evaluation of Compounds on Axenic and Intramacrophage Amastigotes

The evaluations of activity on axenic amastigotes were adapted from the protocols previously described [29]. Briefly, two-fold serial dilutions of the compounds, from 100 µM to 0.049 µM, were performed in 100 µL of complete medium (see above) in 96-well microplates Axenic amastigotes were then added to each well at a density of 106/mL in 200 µL final volume. After 72 h of incubation at 37 °C with 5% CO2, 20 µL of resazurin (450 µM) was added to each well and further incubated in the dark for 24 h at 37 °C with 5% CO2. Cell viability was then monitored as described above. The activity of the compounds was expressed as IC50, which was determined by nonlinear regression using GraphPad Prism 7.0. Miltefosine was used as the reference drug.
Concerning the evaluation on intramacrophage amastigotes, the determination of the cytotoxicity as presented above was necessary to use the highest drug concentrations to be studied on the intramacrophage amastigote model. The evaluation on the intracellular form on the parasite was performed as previously described [26]. RAW264.7 macrophages were plated in 16-well Lab-Tek chamber slides (Thermo-Fisher Villebon-sur-Yvette, France) at a density of 2 × 104 cells per well and incubated for 24 h at 37 °C with 5% CO2. Axenic amastigotes were differentiated as described above, centrifuged at 2000× g for 10 min, resuspended in DMEM complete medium, and added to each well to reach a 16:1 parasite to macrophage ratio. After 24 h of infection at 37 °C with 5% CO2, extracellular parasites were removed, and DMEM complete medium (100 µL) containing two-fold serial dilutions of the compounds, from 100 µM to 0.049 µM, was added to each well. A positive control treated with 1% DMSO was added to each Lab-tek chamber slide. After 48 h of treatment, the medium was removed and cells were fixed in methanol for 1 min, stained in 10% Giemsa (Merck, Guyancourt, France) for 5 min, and further rinsed in water before observation in phase contrast at the microscope (Olympus CX31; Olympus, Rungis, France). The number of amastigotes was counted by two independent experimenters for a total of 300 macrophages per well and the ratio of amastigotes per macrophage was determined for each condition. This ratio was further compared with the one of the positive controls, considered as 100%, to determine a percentage of inhibition (% I), as follows: % I = 100 − [(ratio of amastigotes per macrophage in treated cells/ratio of amastigotes per macrophages in untreated cells) × 100]. The activity of the compounds was expressed as IC50, which was determined by nonlinear regression using GraphPad Prism 7.0. Miltefosine was used as the reference drug. In vitro antileishmanial evaluations were performed in triplicate in three independent experiments.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27227892/s1, NMR and HRMS spectra of described compounds.

Author Contributions

Conceptualization, S.P. and S.D.; methodology, S.P., C.A., F.R. and S.D.; validation, S.P. and S.D.; formal analysis, G.J., L.N.d.F.C., F.O., I.D., C.A., M.L., F.R., S.P. and S.D. investigation, G.J., L.N.d.F.C., F.O., I.D., F.R., S.P. and S.D.; resources, S.P., M.L., F.R. and S.D.; writing—original draft preparation, S.D.; writing—review and editing, C.A., F.R., S.P. and S.D.; supervision, S.D.; funding acquisition, M.L., F.R., S.P. and S.D. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by an “Investissement d’Avenir” grant managed by Agence Nationale de la Recherche (CEBA, ANR-10-LABX-25-01).

Data Availability Statement

All data are already provided in the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds synthesized are available from the authors.

References

  1. Roatt, B.M.; de Oliveira Cardoso, J.M.; De Brito, R.C.F.; Coura-Vital, W.; de Oliveira Aguiar-Soares, R.D.; Reis, A.B. Recent advances and new strategies on leishmaniasis treatment. Appl. Microbiol. Biotechnol. 2020, 104, 8965–8977. [Google Scholar] [CrossRef] [PubMed]
  2. WHO/Leishmaniasis. Available online: https://www.who.int/health-topics/leishmaniasis#tab=tab_1 (accessed on 7 November 2022).
  3. Pradhan, S.; Schwartz, R.A.; Patil, A.; Grabbe, S.; Goldust, M. Treatment options for leishmaniasis. Clin. Exp. Dermatol. 2022, 47, 516–521. [Google Scholar] [CrossRef] [PubMed]
  4. Olivon, F.; Remy, S.; Grelier, G.; Apel, C.; Eydoux, C.; Guillemot, J.-C.; Neyts, J.; Delang, L.; Touboul, D.; Roussi, F.; et al. Antiviral compounds from Codiaeum peltatum targeted by multi-informative network approach. J. Nat. Prod. 2019, 82, 330–340. [Google Scholar] [CrossRef] [PubMed]
  5. Olivon, F.; Apel, C.; Retailleau, P.; Allard, P.M.; Wolfender, J.L.; Touboul, T.; Litaudon, M.; Desrat, S. Searching for original natural products by molecular networking: Detection, isolation and total synthesis of chloroaustralasines. Org. Chem. Front. 2018, 5, 2171–2178. [Google Scholar] [CrossRef]
  6. Riveira, M.J.; La-Venia, A.; Mischne, M.P. Pericyclic cascade toward isochromenes: Application to the synthesis of alkaloid benzosimuline. J. Org. Chem. 2016, 81, 7977–7983. [Google Scholar] [CrossRef] [Green Version]
  7. Dib, M.; Ouchetto, H.; Ouchetto, K.; Hafid, A.; Khouili, M. Recent developments of quinoline derivatives and their potential biological activities. Curr. Org. Synth. 2021, 18, 248–269. [Google Scholar] [CrossRef]
  8. Pérez-Pertejo, Y.; Reguera, R.M.; Carbajo-Andrés, R.; Balana-Fouce, R.; Alonso, C.; Martin-Encinas, E.; Selas, A.; Rubiales, G.; Palacios, F. Antileishmanial activity of new hybrid tetrahydroquinoline and quinoline derivatives with phosphorous substituents. Eur. J. Med. Chem. 2019, 162, 18–31. [Google Scholar]
  9. Barak Almandil, N.; Taha, M.; Rahim, F.; Wadood, A.; Imran, S.; Alqahtani, M.A.; Bamarouf, Y.A.; Ibrahim, M.; Mosaddik, A.; Gollapalli, M. Synthesis of novel quinoline-based thiadazole, evaluation of their antileishmanial potential and molecular docking studies. Biorg. Chem. 2019, 85, 109–116. [Google Scholar] [CrossRef]
  10. Carlos Coa, J.; Cardona-Galeano, W.; Restrepo, A. Fe3+ chelating quinoline-hydrazone hybrids with proven cytotoxicity, leishmanicidal, and trypanocidal activities. Phys. Chem. Chem. Phys. 2018, 20, 20382–20390. [Google Scholar]
  11. Sharma, M.G.; Vala, R.M.; Patel, H.M. Pyridine-2-carboxylic acid as an effectual catalyst for rapid multi-component synthesis of pyrazolo[3,4-b]quinolinones. RSC Adv. 2020, 10, 35499–35504. [Google Scholar] [CrossRef]
  12. Patel, S.G.; Vala, R.M.; Patel, P.J.; Upadhyay, D.B.; Ramkumar, V.; Gardas, R.L.; Patel, H.M. Synthesis, crystal structure and in silico studies of novel 2,4-dimethoxy-tetrahydropyrimido[4,5-b]quinoline-6(7H)-ones. RSC Adv. 2022, 12, 18806–18820. [Google Scholar] [CrossRef] [PubMed]
  13. Solomon, V.R.; Lee, H. Quinoline as privileged scaffold in cancer drug discovery. Curr. Med. Chem. 2011, 18, 1488–1508. [Google Scholar] [CrossRef] [PubMed]
  14. Loiseau, P.M.; Balaraman, K.; Barratt, G.; Pomel, S.; Durand, R.; Frézard, F.; Figadère, B. The potential of 2-substituted quinolines as antileishmanial drug candidates. Molecules 2022, 27, 2313. [Google Scholar] [CrossRef] [PubMed]
  15. Billo, M.; Fournet, A.; Cabalion, P.; Waikedre, J.; Bories, C.; Loiseau, P.; Prina, E.; Rojas de Arias, A.; Yaluff, G.; Fourneau, C.; et al. Screening of New Caledonian and Vanuatu medicinal plants for antiprotozoal activity. J. Etnopharmacol. 2005, 96, 569–575. [Google Scholar] [CrossRef]
  16. Lee, Y.R.; Kweon, H.I.; Koh, W.S.; Min, K.R.; Kim, Y.; Lee, S.H. One-pot preparation of pyranoquinolinones by ytterbium(III) trifluoromethanesulfonate-catalyzed reactions: Efficient synthesis of flindersine, N-methylflindersine, and zanthosimuline natural products. Synthesis 2001, 12, 1851–1855. [Google Scholar] [CrossRef]
  17. Wang, X.; Lee, Y.R. Efficient synthesis of substituted pyranoquinolinones from 2,4-dihydroxy quinoline: Total synthesis of zanthosimuline, cis-3′,4′-dihydroxy-3′,4′-di hydroflindersine, and orixalone D. Synthesis 2007, 19, 3044–3050. [Google Scholar]
  18. Wu, S.-J.; Chen, I.-S. Alkaloids from Zanthoxylum Simulans. Phytochemistry 1993, 34, 1659–1661. [Google Scholar]
  19. Caprioglio, D.; Mattoteia, D.; Minassi, A.; Pollastro, F.; Lopatriello, A.; Munoz, E.; Taglialatela-Scafati, O.; Appendino, G. One-pot total synthesis of cannabinol via iodine-mediated deconstructive annulation. Org. Lett. 2019, 21, 6122–6125. [Google Scholar] [CrossRef]
  20. Burchill, L.; Day, A.J.; Yahiaoui, O.; George, J.H. Biomimetic total synthesis of the rubiginosin meroterpenoids. Org. Lett. 2021, 23, 578–582. [Google Scholar] [CrossRef]
  21. Lin, S.; Ischay, M.A.; Fry, C.G.; Yoon, T.P. Radical cation Diels-Alder cycloaaditions by visible light photocatalysis. J. Am. Chem. Soc. 2011, 133, 19350–19353. [Google Scholar] [CrossRef] [Green Version]
  22. Luo, G.-Y.; Wu, H.; Li, H.; Yeom, H.-S.; Yang, K.; Hsung, R.P. A Total synthesis of (±)-rhododaurichromanic acid A via an oxa-[3+3] annulation of resorcinols. Synthesis 2015, 47, 2713–2720. [Google Scholar]
  23. Zahid, M.S.H.; Johnson, M.M.; Tokarski, R.J., 2nd; Satoskar, A.R.; Fuchs, J.R.; Bachelder, E.M.; Ainslie, K.M. Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani. Int. J. Parasitol. Drugs Drug Resist. 2019, 10, 125–132. [Google Scholar] [CrossRef] [PubMed]
  24. De Muylder, G.; Vanhollebeke, B.; Caljon, G.; Wolfe, A.R.; McKerrow, J.; Dujardin, J.C. Naloxonazine, an amastigote-specific compound, affects Leishmania parasites through modulation of host-encoded functions. PLoS Negl. Trop. Dis. 2016, 10, e0005234. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Gupta, N.; Noël, R.; Goudet, A.; Hinsinger, K.; Michau, A.; Pons, V.; Abdelkafi, H.; Secher, T.; Shima, A.; Shtanko, O.; et al. Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales. Chem. Biol. Interact. 2017, 267, 96–103. [Google Scholar] [CrossRef] [Green Version]
  26. Levaique, H.; Pamlard, O.; Apel, C.; Bignon, J.; Arriola, M.; Kuhner, R.; Awang, K.; Loiseau, P.M.; Litaudon, M.; Pomel, S. Alkyl-resorcinol derivatives as inhibitors of GDP-mannose pyrophosphorylase with antileishmanial activities. Molecules 2021, 26, 1551. [Google Scholar] [CrossRef]
  27. Coleman, M.A.; Burchil, L.; Sumby, C.J.; George, J.H. Biomimetic synthesis enables the structure revision of furoerioaustralasine. Org. Lett. 2019, 21, 8776–8778. [Google Scholar] [CrossRef]
  28. Armarego, W.L.F.; Chai, C.L.L. Purification of Laboratory Chemicals, 7th ed.; Butterworth-Heinemann: Oxford, UK, 2013. [Google Scholar]
  29. Saar, Y.; Ransford, A.; Waldman, E.; Mazareb, S.; Amin-Spector, S.; Plumblee, J.; Turco, S.J.; Zilberstein, D. Characterization of developmentally-regulated activities in axenic amastigotes of Leishmania donovani. Mol. Biochem. Parasitol. 1998, 95, 9–20. [Google Scholar] [CrossRef]
Molecules 27 07892 g001 550
Figure 1. Structures of codiapeltine B (1), actephilol B (2), and chlororaustralasines A and B (3,4) isolated from the bark extract of Codiaeum peltatum.
Figure 1. Structures of codiapeltine B (1), actephilol B (2), and chlororaustralasines A and B (3,4) isolated from the bark extract of Codiaeum peltatum.
Molecules 27 07892 g001
Molecules 27 07892 sch001 550
Scheme 1. Biomimetic synthesis of chloroaustralasine A 3: (a) Ethylenediamine-N,N’-diacetic acid (EDDA, 0.2 eq.), EtOH, 150 °C (MW), 20 min, 92%; (b) Me2AlCl (2 eq.), CH2Cl2, RT, 18 h, 95%, cis/trans 2:1; (c) chloroperoxidase (120 U), NaCl (1 eq.), H2O2 (1 eq.), t-BuOH/citric acid buffer (0.1 M, pH 3.5) 1:3, r.t., 1 h, 26%.
Scheme 1. Biomimetic synthesis of chloroaustralasine A 3: (a) Ethylenediamine-N,N’-diacetic acid (EDDA, 0.2 eq.), EtOH, 150 °C (MW), 20 min, 92%; (b) Me2AlCl (2 eq.), CH2Cl2, RT, 18 h, 95%, cis/trans 2:1; (c) chloroperoxidase (120 U), NaCl (1 eq.), H2O2 (1 eq.), t-BuOH/citric acid buffer (0.1 M, pH 3.5) 1:3, r.t., 1 h, 26%.
Molecules 27 07892 sch001
Molecules 27 07892 sch002 550
Scheme 2. Pharmacomodulations of zanthosimuline 7: (a) EDDA (0.2 eq.), EtOH, 150 °C (MW), 30 min, 87%; (b) NaH (1.2 eq.), DMF, 0 °C, 30 min then addition of the electrophile (2 eq.), 0 °C to RT, 18 h; (c) LiOH.H2O (3 eq.), MeOH/H2O 1:1, RT, 18 h.
Scheme 2. Pharmacomodulations of zanthosimuline 7: (a) EDDA (0.2 eq.), EtOH, 150 °C (MW), 30 min, 87%; (b) NaH (1.2 eq.), DMF, 0 °C, 30 min then addition of the electrophile (2 eq.), 0 °C to RT, 18 h; (c) LiOH.H2O (3 eq.), MeOH/H2O 1:1, RT, 18 h.
Molecules 27 07892 sch002
Molecules 27 07892 sch003 550
Scheme 3. Cyclization of zanthosimuline analog 15a: SnCl4 (2 eq.), CH2Cl2, RT, 1 h.
Scheme 3. Cyclization of zanthosimuline analog 15a: SnCl4 (2 eq.), CH2Cl2, RT, 1 h.
Molecules 27 07892 sch003
Table
Table 1. Results obtained after the screening of reaction conditions for the cyclization of zanthosimuline 7 into tetracyclic alkaloid 8.
Table 1. Results obtained after the screening of reaction conditions for the cyclization of zanthosimuline 7 into tetracyclic alkaloid 8.
Molecules 27 07892 i001
EntryReaction ConditionsConversion *Results (Isolated Yield)
1Silica, neat, 150 °C, 1 h100%Complex mixture, 8: 26%
2MeNO2, 150 °C, 1 h100%8: 44%
3H2SO4 (0.01 eq.), CH2Cl2, RT, 1 h100%Complex mixture **
4PTSA.H2O (2 eq.), CH2Cl2, RT, 24 h20%Complex mixture **
5Montmorillonite K10, CH2Cl2, RT, 18 h5%8: 2%, 10: 2%
6TMSCl (2 eq.), CH2Cl2, RT, 1 h20%Complex mixture **
7BF3.OEt2 (2 eq.), CH2Cl2, RT, 18 h100%10: 30%, 11: 28%
8TiCl4 (2 eq.), CH2Cl2, RT, 1 h100%Complex mixture, 10: 10%, 11: 36%
9SnCl4 (2 eq.), CH2Cl2, RT, 1 h100%10: 95%
10ZnCl2 (2 eq.), CH2Cl2, RT, 1 h<5%−
11FeCl3 (2 eq.), CH2Cl2, RT, 24 h<5%−
12AlCl3 (2 eq.), CH2Cl2, RT, 1 h100%Complex mixture **
13AlMe3 (2 eq.), CH2Cl2, RT, 24 h80%8: 55%, 9: 10%
14Me2AlCl (2 eq.), CH2Cl2, RT, 18 h100%8: 95%
15Ru(bpy)3(PF6)2 (0.05 eq.), MeNO2, RT, 24 h100%12: 86%
* The conversions of 7 into products were calculated from the 1H NMR spectrum of the crude mixture. ** No product could be purified and identified.
Table
Table 2. Results of the evaluation of compounds 3, 4, 7, 11, and 12 on L. infantum axenic and intramacrophagic amastigotes, cytotoxicity, and corresponding selectivity index.
Table 2. Results of the evaluation of compounds 3, 4, 7, 11, and 12 on L. infantum axenic and intramacrophagic amastigotes, cytotoxicity, and corresponding selectivity index.
EntryCompoundL. infantum
Axenic Amastigotes
IC50 (µM) ± S.D.		L. infantum
Intramacrophagic Amastigotes
IC50 (µM) ± S.D.		Cytotoxicity
on RAW 264.7
CC50 (µM) ± S.D.		Selectivity
Index *
138.1 ± 1.4>5080.8 ± 8.0<1.6
2418.6 ± 2.5>6.258.3 ± 3.2<1.3
3729.1 ± 1.0>10075.9 ± 1.8<0.8
411>10014.7 ± 1.6>100>6.8
51242.6 ± 2.1>5063.2 ± 2.5<1.3
6Miltefosine **1.0 ± 0.36.7 ± 1.754.2 ± 5.88.1
* Selectivity index = CC50/IC50 on intramacrophage amastigotes. ** Reference compound.
Table
Table 3. Results of the evaluation of compounds 7, 14, 15a–l, and 16a on L. infantum axenic and intramacrophagic amastigotes, cytotoxicity, and corresponding selectivity index.
Table 3. Results of the evaluation of compounds 7, 14, 15a–l, and 16a on L. infantum axenic and intramacrophagic amastigotes, cytotoxicity, and corresponding selectivity index.
EntryCompoundL. infantum
Axenic Amastigotes
IC50 (µM) ± S.D.		L. infantum
Intramacrophagic Amastigotes
IC50 (µM) ± S.D.		Cytotoxicity
on RAW 264.7
CC50 (µM) ± S.D.		Selectivity
Index *
11415.6 ± 1.8>10075.9 ± 1.8<1.1
215a16.8 ± 1.823.7 ± 6.5>100>4.2
315b15.0 ± 1.7>2542.7 ± 6.6<1.7
415c14.2 ± 4.3>2531.1 ± 10.6<1.2
515d17.8 ± 2.3>2547.8 ± 13.8<1.9
615e21.9 ± 0.6>2544.8 ± 2.3<1.8
715f9.8 ± 2.9>5052.3 ± 4.7<1.1
815g82.7 ± 6.529.5 ± 9.9>100<3.4
915h>100>100>100−
1015i12.9 ± 3.2>1518.1 ± 2.6<1.2
1115j9.1 ± 0.4>2527.8 ± 1.6<1.1
1215k14.6 ± 2.119.0 ± 2.234.4 ± 4.01.8
1315l16.4 ± 1.7>100>100
1416a7.0 ± 2.1>2544.0 ± 10.0<1.8
15729.1 ± 1.0>10075.9 ± 1.8<0.8
16Miltefosine **1.0 ± 0.36.7 ± 1.754.2 ± 5.88.1
* Selectivity index = CC50/IC50 on intramacrophage amastigotes. ** Reference compound.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Jézéquel, G.; Cardoso, L.N.d.F.; Olivon, F.; Dennemont, I.; Apel, C.; Litaudon, M.; Roussi, F.; Pomel, S.; Desrat, S. Synthesis and Anti-Leishmanial Properties of Quinolones Derived from Zanthosimuline. Molecules 2022, 27, 7892. https://doi.org/10.3390/molecules27227892

AMA Style

Jézéquel G, Cardoso LNdF, Olivon F, Dennemont I, Apel C, Litaudon M, Roussi F, Pomel S, Desrat S. Synthesis and Anti-Leishmanial Properties of Quinolones Derived from Zanthosimuline. Molecules. 2022; 27(22):7892. https://doi.org/10.3390/molecules27227892

Chicago/Turabian Style

Jézéquel, Gwenaëlle, Laura Nogueira de Faria Cardoso, Florent Olivon, Indira Dennemont, Cécile Apel, Marc Litaudon, Fanny Roussi, Sébastien Pomel, and Sandy Desrat. 2022. "Synthesis and Anti-Leishmanial Properties of Quinolones Derived from Zanthosimuline" Molecules 27, no. 22: 7892. https://doi.org/10.3390/molecules27227892

Article Metrics

Back to TopTop